Back to search results

Long-term Monitoring After AUTO CAR T Cell Therapy

This study is following people who have already received AUTO CAR T cell therapy for cancers like multiple myeloma, DLBCL (a type of lymphoma), ALL (a type of leukemia), and T cell lymphoma. The main goal is to understand the long-term safety of this treatment by tracking any serious side effects, new cancers, or other specific problems that might appear up to 15 years after treatment. You can join if you've already had AUTO CAR T cell therapy on a clinical study, have given your consent for this long-term follow-up, and can meet the study requirements. This study is currently unclear about its recruitment status and plans to enroll up to 500 participants.

Study design
This is an interventional study that will follow up to 500 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 15 years after their first AUTO CAR T cell therapy infusion to monitor for long-term effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03628612

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

Enrolling by Invitation
PHASE2Ages 1+Interventional
Autolus Limited
~500 participants
Updated 2025-08-07 on ClinicalTrials.gov
What's tested:AUTO CAR T cell therapy

At a glance

Recruiting sites
0 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Serious Adverse Events (SAE), new malignancies & adverse events of special interest (AESI) related to AUTO CAR T cell therapy
Measured over For up to 15 years

Conditions

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
Multiple Myeloma
DLBCL
ALL, Adult and Pediatric
T Cell Lymphoma

Explore related trials

Acute Lymphoblastic LeukemiaDiffuse Large B-Cell LymphomaMultiple MyelomaT-Cell Non-Hodgkin Lymphoma

NCT03628612

Where you'd take part

This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdomno site contact published

  • Manchester Royal Infirmary Hospital

    Manchester, United Kingdomno site contact published

  • Queen Elizabeth University Hospital

    Glasgow, United Kingdomno site contact published

  • Royal Manchester Children's Hospital

    Manchester, United Kingdomno site contact published

  • St David's South Austin Medical Center

    Austin, Texasno site contact published

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdomno site contact published

  • University of Miami

    Miami, Floridano site contact published

  • Washington University in St. Louis

    St Louis, Missourino site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Incidence of Serious Adverse Events (SAE), new malignancies & adverse events of special interest (AESI) related to AUTO CAR T cell therapyFor up to 15 years

    Monitoring of all SAEs / AESIs, including any new malignancy or new diagnosis of neurologic disorders, or other hematologic disorder, related to AUTO CAR T cell therapy. Monitoring of all adverse events of special interest related to AUTO CAR T cell therapy infusion.